Want to join the conversation?
For 2Q16, $AKAM projects non-GAAP OpEx to be $206-211MM. CapEx is expected to be about $90-98MM, excluding equity compensation. Non-GAAP depreciation expense is expected to be $73-75MM. Tax is expected to be $46-48MM based on estimated non-GAAP tax rate of 29.5%. Company expects fully diluted share count of 176MM shares in 2Q16.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.